In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report). The company’s shares closed yesterday at $9.66.
Confident Investing Starts Here:
According to TipRanks, Lee is a 5-star analyst with an average return of 17.8% and a 46.21% success rate. Lee covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Intellia Therapeutics, and Argenx Se.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intellia Therapeutics with a $30.86 average price target, a 219.46% upside from current levels. In a report released today, Bernstein also assigned a Buy rating to the stock with a $45.00 price target.
NTLA market cap is currently $965.9M and has a P/E ratio of -1.85.
Source: theglobeandmail.com
